These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 29555153)

  • 21. M100907 and BD 1047 attenuate the acute toxic effects of methamphetamine.
    Ray A; Canal CE; Ehlen JC; Rice KC; Murnane KS
    Neurotoxicology; 2019 Sep; 74():91-99. PubMed ID: 31163210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blockade of serotonin 2A receptors prevents PCP-induced attentional performance deficit and CREB phosphorylation in the dorsal striatum of DBA/2 mice.
    Pozzi L; Greco B; Sacchetti G; Leoni G; Invernizzi RW; Carli M
    Psychopharmacology (Berl); 2010 Feb; 208(3):387-99. PubMed ID: 19997843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease.
    McFarland K; Price DL; Bonhaus DW
    Behav Pharmacol; 2011 Oct; 22(7):681-92. PubMed ID: 21921840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endogenous serotonin and serotonin2C receptors are involved in the ability of M100907 to suppress cortical glutamate release induced by NMDA receptor blockade.
    Calcagno E; Carli M; Baviera M; Invernizzi RW
    J Neurochem; 2009 Jan; 108(2):521-32. PubMed ID: 19046357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens.
    Bonaccorso S; Meltzer HY; Li Z; Dai J; Alboszta AR; Ichikawa J
    Neuropsychopharmacology; 2002 Sep; 27(3):430-41. PubMed ID: 12225700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-based design of PDZ ligands as inhibitors of 5-HT(2A) receptor/PSD-95 PDZ1 domain interaction possessing anti-hyperalgesic activity.
    Vogrig A; Dorr L; Bouzidi N; Boucherle B; Wattiez AS; Cassier E; Vallon G; Ripoche I; Abrunhosa-Thomas I; Marin P; Nauton L; Thery V; Courteix C; Lian LY; Ducki S
    ACS Chem Biol; 2013 Oct; 8(10):2209-16. PubMed ID: 23895101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Responding for a conditioned reinforcer, and its enhancement by nicotine, is blocked by dopamine receptor antagonists and a 5-HT(2C) receptor agonist but not by a 5-HT(2A) receptor antagonist.
    Guy EG; Fletcher PJ
    Pharmacol Biochem Behav; 2014 Oct; 125():40-47. PubMed ID: 25158104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural combination of established 5-HT(2A) receptor ligands: new aspects of the binding mode.
    Kramer V; Herth MM; Santini MA; Palner M; Knudsen GM; Rösch F
    Chem Biol Drug Des; 2010 Oct; 76(4):361-6. PubMed ID: 20636331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rodent data and general hypothesis: antipsychotic action exerted through 5-Ht2A receptor antagonism is dependent on increased serotonergic tone.
    Martin P; Waters N; Schmidt CJ; Carlsson A; Carlsson ML
    J Neural Transm (Vienna); 1998; 105(4-5):365-96. PubMed ID: 9720968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inverse agonists of the 5-HT
    Malin D; Henceroth M; Rao GS; Campbell J; Ma JN; Tsai PH; Kishbaugh JC; Burstein ES
    Neurosci Lett; 2019 Nov; 713():134524. PubMed ID: 31585211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proof of concept study for designed multiple ligands targeting the dopamine D2, serotonin 5-HT2A, and muscarinic M1 acetylcholine receptors.
    Szabo M; Lim HD; Herenbrink CK; Christopoulos A; Lane JR; Capuano B
    J Med Chem; 2015 Feb; 58(3):1550-5. PubMed ID: 25590655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and biological investigation of new equatorial (β) stereoisomers of 3-aminotropane arylamides with atypical antipsychotic profile.
    Stefanowicz J; Słowiński T; Wróbel MZ; Herold F; Gomółka AE; Wesołowska A; Jastrzębska-Więsek M; Partyka A; Andres-Mach M; Czuczwar SJ; Łuszczki JJ; Zagaja M; Siwek A; Nowak G; Żołnierek M; Bączek T; Ulenberg S; Belka M; Turło J
    Bioorg Med Chem; 2016 Sep; 24(18):3994-4007. PubMed ID: 27377863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. M100907, a selective 5-HT2A receptor antagonist and a potential antipsychotic drug, facilitates N-methyl-D-aspartate-receptor mediated neurotransmission in the rat medial prefrontal cortical neurons in vitro.
    Arvanov VL; Wang RY
    Neuropsychopharmacology; 1998 Mar; 18(3):197-209. PubMed ID: 9471117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 18F-labeling and evaluation of novel MDL 100907 derivatives as potential 5-HT2A antagonists for molecular imaging.
    Debus F; Herth MM; Piel M; Buchholz HG; Bausbacher N; Kramer V; Lüddens H; Rösch F
    Nucl Med Biol; 2010 May; 37(4):487-95. PubMed ID: 20447561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes.
    Borroto-Escuela DO; Romero-Fernandez W; Narvaez M; Oflijan J; Agnati LF; Fuxe K
    Biochem Biophys Res Commun; 2014 Jan; 443(1):278-84. PubMed ID: 24309097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 5HT
    Amodeo DA; Rivera E; Cook EH; Sweeney JA; Ragozzino ME
    Genes Brain Behav; 2017 Mar; 16(3):342-351. PubMed ID: 27717169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 5-HT 2A and 5-HT 2C receptor antagonism differentially modulate reinforcement learning and cognitive flexibility: behavioural and computational evidence.
    Hervig ME; Zühlsdorff K; Olesen SF; Phillips B; Božič T; Dalley JW; Cardinal RN; Alsiö J; Robbins TW
    Psychopharmacology (Berl); 2024 Aug; 241(8):1631-1644. PubMed ID: 38594515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and biological evaluation of 4-nitroindole derivatives as 5-HT2A receptor antagonists.
    Hayat F; Viswanath AN; Pae AN; Rhim H; Park WK; Choo HY
    Bioorg Med Chem; 2015 Mar; 23(6):1313-20. PubMed ID: 25684421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risperidone and the 5-HT2A receptor antagonist M100907 improve probabilistic reversal learning in BTBR T + tf/J mice.
    Amodeo DA; Jones JH; Sweeney JA; Ragozzino ME
    Autism Res; 2014 Oct; 7(5):555-67. PubMed ID: 24894823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 16p11.2 deletion syndrome mice perseverate with active coping response to acute stress - rescue by blocking 5-HT2A receptors.
    Panzini CM; Ehlinger DG; Alchahin AM; Guo Y; Commons KG
    J Neurochem; 2017 Dec; 143(6):708-721. PubMed ID: 28948999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.